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CHAPTER 7 
Evaluating the immunogenicity 
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(Multimeric-001) either as a standalone 
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ABSTRACT
Introduction Influenza is a major respiratory viral infection of humans with high mortality 
and morbidity rates and profound economic impact. Although influenza vaccines are generally 
updated yearly to match the viruses expected in the coming season, genetic mutation and 
reassortment can result in unexpected novel strains. Therefore, it is important to develop 
universal vaccines inducing protective immunity to such strains before they appear. This 
clinical trial is designed to evaluate the safety and immunogenicity of Multimeric-001 (M-
001), which contains conserved epitopes of influenza A and B. M-001 is able to induce both 
humoral and cellular immunity and provides broad strain coverage.
Methods In a multicenter, randomized, double-blind, and controlled phase IIb trial, 222 
healthy volunteers aged 18 to 60 years will be randomized into 3 groups (1:1:1) to receive either 
2 intramuscular injections of 0.5 mg M-001 (arm 1), 1.0 mg M-001 (arm 2), or saline (arm 
3-placebo), before receiving an investigational (whole virus, inactivated, aluminum phosphate 
gel [AlPO4]-adjuvanted) prepandemic influenza vaccine (H5N1). Primary outcomes are safety 
and cellular immune responses (cell-mediated immunity [CMI]) induced by M-001, evaluated 
by multiparametric flow cytometry of intracellular cytokines. The secondary outcome is the 
serum hemagglutination inhibition (HAI) titer toward the H5N1 vaccine strain. Additionally, 
exploratory outcomes include evaluation of CMI by quantitative reverse transcription 
polymerase chain reaction of cytokine mRNA, HAI titers toward H5-drifted strains, serum 
single radial hemolysis titers toward the H5N1 study vaccine, and the association between 
CMI markers and antibody response.
Discussion There is a need for influenza vaccines that give the population a broader protection 
against multiple strains of influenza virus. M-001 might be such vaccine which will be tested in 
this current trial as a standalone vaccine and as a pandemic primer. Both cellular and humoral 
immune responses will be evaluated.




Influenza is a globally important respiratory viral infection of humans that is easily transmitted 
from person to person.[1] As well as causing annual epidemics during the winter period, newly 
emerging variants can result in global pandemics.[1,2] Infection of humans with influenza virus 
is characterized by symptoms such as a sudden onset of high fever and coughing. Although 
most symptoms are self-limiting and resolved within 1 week, influenza can cause severe illness 
such as pneumonia and otitis media due to the primary influenza infection or to a secondary 
bacterial infection.[1,3–6] Severe illness can result in hospitalizations and deaths, in particular 
among individuals who are at high risk for complications (e.g., children younger than 2 years 
of age, adults aged ≥65 years, pregnant women, and patients with a chronic disease or a 
weakened immune system).[2,4,6] According to the World Health Organization (WHO) up to 
3 to 5 million cases of severe illness occur worldwide during an annual epidemic, resulting in 
250,000 to 500,000 deaths, depending on the severity of the influenza season.[6,7] In addition 
to the morbidity and mortality, these annual epidemics have an enormous economic impact, 
both from the costs of treatment (direct costs) and the high levels of work absenteeism (indirect 
costs).[6,7] The total estimated cost of an influenza epidemic in industrialized countries may 
reach 56.7 million euros per million of population. [7]
The most (cost)-effective way to prevent influenza virus infection and severe illness is 
vaccination.[6,8] Vaccines are designed to induce the immune responses that would be 
normally induced by natural infection, but without causing the disease.[9] Commercially 
available influenza vaccines contain 2 viral surface antigens, the hemagglutinin (HA) and 
neuraminidase (NA).[8,10] HA is responsible for both the attachment of the virus to the sialic-
acid-containing receptors on the host cell surface and the entry of the virus into the host cells, 
whereas NA releases newly formed virus particles from the cell surface.[8,10] The vaccines 
elicit antibodies toward these proteins, thereby limiting or eliminating their function.[10] 
Many countries recommend yearly vaccination against seasonal flu for individuals who are 
at high risk for complications and for people who live with or care for high-risk individuals.
[1,6] Each year, the WHO recommends which virus strains should be included in the seasonal 
influenza vaccine, usually 2 circulating strains of the influenza A (H1N1 and H3N2) virus and 
1 or 2 strains of influenza B virus (Yamagata and/or Victoria lineage).[1,2,6,8] The seasonal 
vaccine must be updated every year due to the minor amino acid changes (antigenic drifts) that 
occur in the HA and NA viral surface proteins.[1,8,11] These antigenic drifts, resulting from 
genetic mutations during viral replication, occur gradually over time, eventually result in the 
unpredictable appearance of new virus strains that may not be effectively recognized by the 
immune system.[11] Occasionally, an abrupt and major change (antigenic shift) in the influenza 
A virus may occur resulting in the introduction of a completely new influenza A subtype that 
has not previously circulated among humans.[1,2,8,11] These viruses are introduced either by 
the direct transfer of an avian influenza virus to humans or by reassortment between human 
and avian viruses after coinfection of another animal serving as a “mixing vessel” (e.g., ducks 
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and pigs).[1,12] Being entirely novel, such shifted viruses are poorly recognized (if at all) by the 
pre-existing immunity to other virus and may be highly contagious and highly pathogenic, 
resulting in a pandemic characterized by many more cases of severe illness.[1,2,11]
One of the most important factors, which influences the type and subtype-specific 
effectiveness of a vaccine, is the degree of similarity between the vaccine virus strains and 
the circulating strains.[13] A vaccine can reduce the risk of illness by 50% to 60% among the 
overall population during seasons when most circulating virus strains are similar to the vaccine 
strains.[13,14] However, the Centers for Diseases Control and Prevention (CDC) in the United 
States estimated that the vaccine effectiveness for the Northern hemisphere in the 2014 to 2015 
influenza season was only 23% (95% confidence interval [CI]: 14–31) in the general population.
[15] This low efficacy is considered to be the result of the mismatch between the H3N2 contained 
in the vaccine (A/Texas/50/12) and the circulating H3N2 virus (A/Switzerland/9715293/13) 
and resulted in the highest recorded rate of flu-associated hospitalization (266.1 per 100,000) 
among adults aged 65 and older in the United States since the CDC started tracking data.
[13,15–18] This mismatch highlights the need for influenza vaccines that give the population a 
broader protection against multiple strains of influenza virus: a universal vaccine.[10,19]
Multimeric-001 (M-001), developed by BiondVax Pharmaceuticals Ltd. (Israel), is designed 
to be a universal influenza vaccine that confers immunity and protection against a broad range 
of influenza viruses. M-001 is a single recombinant protein containing 9 B- and T-cell conserved 
epitopes (epitopes that do not undergo antigenic change) from the HA, nucleoprotein, and 
matrix 1 proteins of both the influenza A and B virus strains. The vaccine induces both humoral 
and cellular immunity.[20,21] In this phase IIb trial, the immunogenicity and safety ofM-
001 and its administration prior to an aluminum phosphate gel (AlPO4)-adjuvanted H5N1 
investigational influenza vaccine product (Fluart Innovative Vaccines Ltd., Hungary) will be 
evaluated in healthy adults (aged 18–60 years). FluartH5N1 vaccine is highly immunogenic at 
doses of 6 and 12mg and hence, a suboptimal dose of the vaccine (3mg) will be used to evaluate 
the dose sparing potential of M-001 and to show its ability to enhance immunogenicity of the 
strain-specific vaccine.[22] The immunogenicity of M-001 both as a standalone vaccine and as 
a pandemic primer will be evaluated. In addition, the association between the cell-mediated 
immunity (CMI) markers and the antibody responses will be evaluated as an exploratory 
endpoint. The safety will be evaluated based on the reported adverse events (AEs) and serious 





The study is a multicenter, randomized, double-blind, and controlled phase IIb trial involving 
222 healthy volunteers aged 18 to 60 years over a period of 187 days (from screening to 
study conclusion). Individuals volunteering to participate in the study will be screened 
before enrollment in the trial. Subject eligibility will be assessed during the screening and 
written consent will be obtained (Fig. 1). The eligible subjects will be randomized to receive 
2 administrations of M-001 at low or high dose, or saline as placebo. All participants will 
receive an investigational AlPO4-adjuvanted, inactivated whole virus prepandemic H5N1 
vaccine as a third administration to evaluate whether M-001 has a priming effect. The H5N1 
vaccine is based on a clade 1 virus A/Vietnam/1194/04. Each administration will be given 
intramuscularly (i.m.) 21±2 days apart. Blood samples will be taken from all subjects on days 
0 (before the first vaccination), 42 (21 days after the second vaccination), and 63 (21 days after 
the H5N1 vaccination) for serum and peripheral blood mononuclear cells (PBMCs) to evaluate 
the influenza-specific cellular and humoral immune responses. Additionally, questionnaires/
diaries concerning AEs will be issued on days 0 and 21 to subjects for the collection of solicited 
(e.g., fever, chills, joint pain, muscle pain, sore throat, fatigue, injection site reactions) and 
unsolicited AEs. The cards will need to be completed by the subjects and returned on day 21 
(second vaccination of study vaccine) and day 42 (H5N1vaccination). Unsolicited AEs and 
SAEs will be followed throughout the whole study period and thereby AEs from both the study 
vaccine and H5N1 vaccine. The study will be conducted at the St. Istvan and St. Laszlo Hospital 
of Budapest (Hungary) and another Hungarian satellite trial site (Béke Hospital, Budapest).
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Figure 1 Flow chart describing the study’s design 
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Individuals will be recruited using advertising material approved by the ethics committee. 
Healthy males and females between the ages of 18 and 60 are eligible for study participation 
(Table 1). Pregnant or breast-feeding women are excluded. Other exclusion criteria include 
individuals who have received an influenza vaccine or have experienced influenza-like illness 
within the 6 months prior to the study, those who are receiving medicines or treatments that 
may affect the evaluation of their immune responses or those who have a history of chronic 
disease and/or immune system disorder (Table 1). Women of childbearing potential and men 
must agree to practice adequate contraception throughout the study treatment and for at 
least up to days 51 and 111 of the trial, respectively, since no reproduction toxicity data are 
known yet. Furthermore, individuals should be able to understand and comply with the study 
procedures. In addition, individuals will only be included if the individual provides a signed 
informed consent form after receiving a detailed explanation of the study protocol prior to any 
study procedures. In case of uncertainty about the medical status of an individual regarding 
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any of the exclusion criteria mentioned, the primary care physician will be consulted. 
Consultation of the primary care physician is included in the consent form and only concerns 
medical information about the exclusion criteria.
Screening and baseline assessment
Baseline assessment during the screening visit will include demographics (i.e., age, gender, 
and ethnicity), general physical examination, self-reported medical and medication history, 
history of influenza vaccination, and alcohol, drug, and cigarette consumption. This is to 
ensure that subjects enter the trial in a healthy condition. A blood sample will be taken at the 
screening visit for laboratory tests including hematology (e.g., hemoglobin, hematocrit, total 
and differential leukocyte count, red blood cell count, platelet count) and serum chemistry 
(e.g., uric acid, creatinine, cholesterol, triglycerides, sodium, potassium). Subjects having an 
abnormal result for any of the tests, upon consultation with the principal investigator, would 
be excluded from the study. In addition to the blood sampling, females will undergo a urine 
pregnancy test. Each screened subject will receive a sequential, unique 5-digit screening 
number which they will retain, whether or not they are ultimately randomized to receive 
treatment. Serum samples from the collected blood at visits 2 and 5 (days 0 and 63) will be 
stored until the end of the trial when serology will be performed to detect antibodies to the 
H5N1 virus and against the 2015–2016 circulating influenza virus strains in order to identify 
subjects having had an asymptomatic influenza infection prior to the start of the trial. On day 
180 of the trial, each participant will receive a phone call for safety follow-up and then the 
study will terminate.
Interventions 
Individuals who meet the eligibility criteria will be randomized (1:1:1) to receive either 
0.5mgM-001 (low dose), 1.0mg M-001 (high dose), or saline (placebo control). All subjects will 
receive 2 i.m. administrations of the test vaccine, or saline, followed by 1 i.m. administration 
of an investigational (whole virus, inactivated, AlPO4-adjuvanted) prepandemic influenza 
vaccine (H5N1) produced by Fluart Innovative Vaccines Ltd (formerly Omninvest Ltd). The 




Table 1 Inclusion and exclusion criteria of individuals 
Inclusion 
criteria 
- Aged between 18 and 60 y
- Men and non-pregnant women as indicated by a negative urine pregnancy test 
- Healthy as determined by vital signs (heart rate, blood pressure, armpit temperature), 
blood chemistry (electrolytes, renal/kidney function, liver function, C-reactive protein, 
complete blood count), medical history, general physical examination, self-reported illness 
and clinical judgment of the investigator
- Women of childbearing potential (not surgically sterile or postmenopausal for ≥ 1 
year) and men must agree to practice adequate contraception (intrauterine device (IUD) 
or a combination of barrier and hormone methods for women and a condom for men) 
throughout the study treatment for at least up to day 51 (for female) and day 111 (for male) 
of the trial (i.e. 30 and 90 days after the last administration of the investigational medicinal 
product
- Able to understand and comply with planned study procedures
- Provides signed informed consent form after receiving a detailed explanation of the study 
protocol prior to any study procedures 
Exclusion 
criteria 
- Known allergy to components of the vaccine (e.g. egg products)
- History of severe reactions following immunizations
- Immune deficiency/disorder, whether due to genetic defect, immunodeficiency disease, or 
immunosuppressive therapy
- Positive urine pregnancy test prior to vaccination or who are breastfeeding
- History of (reported by subjects): 
• Acute disseminated encephalomyelitis (ADEM); 
• Active neoplastic disease;
• Asthma or severe allergic disease;
• Bleeding disorders;
• Chronic hepatitis B and/or C infection;
• Chronic liver disease;
• Diabetes mellitus;
• Guillain-Barre syndrome;
• Human immunodeficiency virus (HIV); 
• Rheumatoid arthritis or other autoimmune diseases;
• Severe renal disease; 
• Transplant recipients;
• Unstable or progressive neurological disorders
- Receipt of medicines/treatment that may affect the evaluation of immunogenicity such as; 
• Oral or parenteral steroids, high-dose inhaled steroids (greater than 800 µg/day of 
beclomethasone dipropionate or equivalent) or other immunosuppressive or cytotoxic 
drugs; 
• Immunoglobulin or other blood products (within the 3 mo prior to vaccination in this 
study); 
• Experimental agent (vaccine, drug, biologic, device, blood product, or medication) 
within 1 mo  prior to vaccination in this study, or expects to receive an experimental 
agent during the study period; 
• Influenza antiviral medication within the 4 wk  prior to the vaccination in this study. 
- Received any influenza vaccine within 6 mo  prior to vaccination in this study. 
- Influenza like-illness within 6 mo  prior to vaccination in this study. 
- Acute illness, including an armpit temperature >  38 degrees oC, within 1 wk  before 
vaccination.
- History of alcohol or drug abuse.
- Any abnormal haematology values and/or serum chemistries judged by the investigator as 
clinically significant. 





The trial has 2 primary outcomes. The first primary outcome is the cellular immune response 
elicited by M-001, evaluated by multiparametric flow cytometry analysis in all subjects on days 
0 and 42. Multiparametric flow cytometry will be performed after 24h in vitro stimulation of 
PBMC with vaccine antigen. Markers including clusters of differentiation 3 (CD-3), CD-4, and 
CD-8 will be used to define cell lineage, and interferon gamma (IFN-g), interleukin (IL)-2, IL-
4, and tumor necrosis factor alpha (TNF-a) will be used to detect specific cytokine responses. 
The other primary outcome is safety evaluation. This includes the solicited AEs in all subjects 
until 21 days after the last dosing of the study vaccine and the unsolicited AEs and SAEs in all 
subjects for 180 days after the first injection. The investigator will assess the intensity of the AE 
and the relationship between the tested vaccine and the occurrence of the AE (Table 2).
Secondary outcomes
The secondary outcome is serum hemagglutination inhibition (HAI) titers specific for the 
H5N1 study vaccine strain (A/Vietnam/1194/2004) in all subjects on days 0 and 63 (21 days 
following the H5N1 vaccination). HAI tests will be performed by standard procedures with 
chicken red blood cells and 4 HA units of virus/well.[23]
Table 2 Adverse events classification
Adverse event intensity
Mild An event that is easily tolerated by the subject, causing minimal discomfort and 
not interfering with everyday activities
Moderate An event that causes sufficient discomfort as to interfere with normal everyday 
activities
Severe An event that prevents normal everyday activities
Serious Any untoward medical occurrence that: 
• Results in death
• Is life threating (an event in which the subject was at risk of death at the time 
of the time)
• Requires hospitalization or prolongation of an existing hospitalization
• Results in disability or permanent damage as defined as a substantial 
disruption of a person’s ability to conduct normal life functions
• Is a congenital anomaly/birth defect 
• Other adverse events that may jeopardize the subject or may require medical 
or surgical intervention to prevent one of the other outcomes
Adverse event causality
Unrelated Where an event is not considered related to the investigational medicinal product
Unlikely Although the relationship to investigational medicinal product cannot be 
completely ruled out, the nature of the event, the underlying disease, concomitant 
medication or temporal relationship make other explanations more likely
Possibly related The temporal relationship and the absence of a more likely explanation suggest the 
event could be related to the investigational medicinal product
Probably related The known effects of the investigational medicinal product or its therapeutic class, 
or based on challenge testing, suggest the investigational medicinal product is the 
most likely cause




The following exploratory outcomes are considered; (1) cellular immune response elicited 
by M-001, with or without prepandemic H5N1 vaccine, evaluated by quantitative reverse 
transcription polymerase chain reaction (qRT-PCR) of cytokine mRNA on days 0, 42, and 63 
in a subset of 60 subjects; (2) serum HAI titers toward H5 drifted strains evaluated on days 0 
and 63 in all subjects; (3) serum single radial hemolysis (SRH) titers evaluated on days 0 and 63 
in all subjects toward the H5N1 vaccine strain; and the association between the CMI markers 
analyzed and (4) the HAI responses.
Sample size calculation
Though a variety of immune parameters will be analyzed during the trial, the minimum 
sample size is determined on the basis of the expression of IFN-g producing CD-8+ cells, as 
this T-cell subset is important for influenza viral clearance.[24,25] We estimated a background 
rate of 5% in the placebo group and it is expected that the M-001 vaccine will result in at 
least 5 times higher rates, or an absolute rate of 25% responders in the vaccinated arms.[21] 
To be able to detect this with a power of 80%, approximately 60 subjects per arm are needed 
based on a 2-group continuity corrected test with a 0.05 two-sided significance level. Taking 
15% loss of follow-up into account, a total of 222 subjects (74 subjects per treatment group) 
is required. It should be noted that estimates are based on data analysis from a previous trial 
where multiparametric flow cytometry analysis was performed on only a small sample size of 
10 elderly participants.
Randomization
Eligible subjects will be randomized 1:1:1 to 1 of the 3 treatment groups. Within each 
treatment group block randomization will be done for participants aged <50 years and ≥50 
years to achieve an approximately balanced age distribution.[26] Randomized subjects will be 
allocated the next sequential 3-digit randomization number available at the trial site which is 
identical to the treatment number allocated by the randomization list. 
Blinding
The study will be double-blinded. To maintain blinding, the preparation of the M-001 
formulations and control will be performed by an unblinded qualified person (QP) other than 
the person giving the injection. The reason for this is that M-001 and saline differ in appearance. 
The unblinded QP will prepare the dosing solutions and will use the study randomization 
code to assign each subject to the appropriate treatment group. The unblinded QP will not 
reveal the treatment code to other study personnel or perform any other study treatment-
related activities. The unblinded QP will prepare syringes containing the study medication 
assigned by the randomization scheme. The syringe content will be hidden by a label, which 
includes the subject’s randomization number, initials, and date of birth. An identical label will 
be attached to the top of the case report form. This material will be given to the blinded study 
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personnel administering the injections. The pharmacy file, including the randomization list, 
vaccine supplies, and all associated documentation, will be stored in a locked cabinet within 
the pharmacy to which only the unblinded pharmacy personnel have access.
Statistical analysis and report
A statistical analysis plan (SAP) will be developed according to the Consolidated Standards 
of Reporting Trials 2010 guidelines before the database lock.[27] Both intention-to-treat 
(ITT) and perprotocol analysis will be performed for the analyses of reported AEs and SAEs, 
themeasured serumHAI titers, SRHtiters, and the cellular immune response measured by both 
multiparametric flow cytometry and qRT-PCR assays. ITT analysis will include all vaccinated 
subjects who receive the first vaccination. Perprotocol analysis will include the subjects who 
complete the assigned schedule of vaccination, who meet the inclusion and exclusion criteria, 
and who comply with the procedures defined in the protocol (i.e., vaccinated according to 
their randomized assignment, not vaccinated with any vaccine or treated with any medication 
not foreseen or forbidden in the protocol, free of underlying medical conditions forbidden by 
the protocol) until the days of assessment and have not broken the randomization code. Both 
analyses will be conducted to assess differences from baseline with their corresponding 95% 
CIs. Differences in continuous variables will be tested using the analysis of variance (ANOVA)/
Ttests or distribution-free tests. In addition, subgroup analyses are preplanned according to 
age (<50 and ≥50 years) and ANOVA or Kruskal–Wallis test will be applied to test for potential 
differences between the treatment groups. All calculations will be performed using SAS for 
Windows. The measured variables and derived parameters will be listed individually by subject 
number and treatment group. The data will be summarized in appropriate tables presenting 
sample size, arithmeticmean, standard deviation, minimum, median, and maximum values by 
treatment group for continuous data and absolute and relative frequency by treatment group 
for categorical data.
Data management
An interactive website will be established which will be the major communication instrument 
ensuring the integration of program communication and the trial study. In addition, electronic 
case report forms will be developed in accordance with the good clinical practice (GCP) 
standards for electronic data entry and flexible data export, and will be integrated into the 
interactive website. The data entered will be backed up on a daily basis, be subject to secure 
access control management to allow secure entry, access, analysis, and export of data by users 
regardless of their locations and be subject to plausibility and consistency checks during the 
entry process to enforce high data integrity. All nominal subject data will be anonymized to 
ensure personal data protection. If several reports taken at different times have to be correlated, 




Ethical approval and authorization of the trial is obtained from the Clinical Pharmacology 
Ethics Committee (Klinikai Farmakológiai Etikai Bizottság) and the Hungarian National 
Institute of Pharmacy and Nutrition (Országos Gyógyszerészeti és Élelmezés-egészségügyi 
Intézet), respectively. The Institutional Ethics Committee of St. Istvan and St. Laszlo Hospital 
was also informed.[28] The trial will be performed in compliance with GCP, the Declaration 
of Helsinki and relevant Hungarian national laws. Written informed consent will be obtained 
from subjects before participation in the trial. The original subject signed and dated informed 
consent form will be stored by the site for 10 years. Other trial data will also be stored for 10 
years. The trial results will be made suitable for publication in international scientific journals.
DISCUSSION
The main objective of this phase IIb trial is to evaluate the safety and immunogenicity of 
M-001 as a standalone universal vaccine and when used as a primer for a pandemic influenza 
vaccine. Currently, the standard criterion to determine influenza vaccine efficacy is based on 
HAI titer.[25,29,30] However, this criterion is not applicable for M-001 since only conserved 
epitopes without hemagglutination and neutralization capacity are included in it.[20,25] 
Previous trials using M-001 have shown that it induces influenza-specific cellular immune 
responses, which are suggested to be important for protection against influenza disease.[31] 
The vaccine efficacy of M-001 will therefore be evaluated by multiparametric flow cytometry 
analysis in the current trial. Flow cytometry is chosen because the assay provides a sensitive 
technique for qualitative and quantitative analyses of cellular immune responses.[25,32] Only 
1 blood sample is needed to simultaneously measure CD-3, CD-4, and CD-8 T-cells and the 
functional markers IFN-g, IL-2, IL-4, and TNF-a for both CD-4 and CD-8 T-cells responses.
[24,25,33] The analysis will be standardized and validated before analyzing the clinical 
samples. In addition to flow cytometry, detection of IFN-g and granzyme B mRNA expression 
by qRT-PCR assay will be performed. This method has recently been shown to be a highly 
sensitive measure for the detection of CMI in guinea pigs immunized intradermally with 
heat-inactivated varicella-zoster virus.[34] The ultimate aim is to develop a set of correlates 
of protection that could improve the translation of immunological data from small clinical 
trials in humans into conclusions about protective efficacy. Currently large clinical trials are 
required for assessing vaccine efficacy (reduction of illness), since the incidence of influenza is 
only ∼5%. If such immunological correlates of protection could be identified, they could serve 
as a surrogate measure of protection in comparatively small trials.
M-001 has been tested as a primer for a seasonal trivalent inactivated influenza vaccine 
(TIV) in adults aged 55 to 75 years and the elderly (over 65 years of age).[21] These studies 
showed that TIV, which was administrated 3 weeks after receiving 1 or 2 administrations 
of M-001 or placebo, with an interval of 21±2 days, induced higher HAI antibody titers in 
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individuals primed with M-001. In addition, M-001 also increased the TIV seroconversion 
rate (percentage of participants with a minimum 4-fold increase in the HAI titer and ≥1:40 
HAI antibody titers) and broadens the antibody responses toward influenza strains other than 
the TIV strains. This indicates that M-001 has the potential to act as a primer for influenza 
vaccines in general which is especially important in the case of weakly immunogenic HA-based 
influenza vaccines, such as a pandemic vaccine. Since it is not feasible to determine the clinical 
efficacy of a pandemic vaccine in a clinical trial and it takes several months to manufacture a 
pandemic vaccine, a prepandemic primer such as M-001 represents a breakthrough in pandemic 
preparedness.[29] Stockpiled M-001 can be administered immediately upon pandemic alert to 
prime the immune response for the pandemic vaccine still under production, irrespective of 
the identified pandemic strain which will be included in the pandemic vaccine. The success of 
this pandemic prime-boost approach is expected to greatly reduce the illness and economic 
loss caused by an upcoming pandemic. To assess the efficacy of this prime-boost approach, 
HAI titers toward the H5N1 study vaccine strain (secondary outcome) and other H5 drifted 
strains (exploratory outcome) induced by the investigational H5 pandemic vaccine, with or 
without M-001 priming, will be evaluated.
Finally, M-001 is a recombinant product, which is produced in Escherichia coli using 
standard fermentation and purifications methods.[20] This is a simple, scalable manufacturing 
process. The vaccine production takes only 6 to 8 weeks and it has the possibility of flexible 
manufacturing year-round, meaning that production can be planned in accordance with 
market demands, enabling national stockpiles to be maintained for all income class countries.
[20,21,35] Furthermore, people with egg-allergies can be vaccinated with the standalone 
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